Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
Apr 26 BMRN BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript
Apr 26 BMRN BioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations
Apr 26 BMRN Pfizer hemophilia gene therapy arrives in US to uncertain future
Apr 25 SNY AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
Apr 25 BMRN Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Apr 25 SNY Sanofi 2024 Q1 - Results - Earnings Call Presentation
Apr 25 BMRN BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Apr 25 SNY 20 Fastest Growing Health Tech Companies in the World
Apr 25 SNY Sanofi (SNY) Q1 2024 Earnings Call Transcript
Apr 25 SNY Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
Apr 25 SNY AstraZeneca Flirts With A Breakout After Cancer Drug Sales Shine; Sanofi, Bristol Stocks Diverge
Apr 25 BMRN BioMarin drops drug programs in pipeline cull
Apr 25 BMRN Q1 2024 Biomarin Pharmaceutical Inc Earnings Call
Apr 25 SNY US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says Analyst
Apr 25 SNY Sanofi Sales, Profit Beat Expectations
Apr 25 BMRN Biomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...
Apr 25 SNY UPDATE 2-Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
Apr 25 SNY Sanofi profit slips on generic competition and currency effects
Apr 25 SNY Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags